Eylea (aflibercept): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Eylea 40mg/ml solution for injection in a vial

Eylea is indicated for adults for the treatment of

• neovascular (wet) age-related macular degeneration (AMD),

• visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),

• visual impairment due to diabetic macular oedema (DME),

• visual impairment due to myopic choroidal neovascularisation (myopic CNV).


Route of administration: Injectable
Molecule: aflibercept

Patients' opinions on Eylea

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.